Toni Choueiri outlines the results of the phase 3 KEYNOTE-564 trial showing the benefit of adjuvant treatment with pembrolizumab in patients with high-risk renal cell carcinoma (3:03).
View more on Medicine Matters oncology: [ Ссылка ]
![](https://i.ytimg.com/vi/x1W9jDlO7cU/maxresdefault.jpg)
Toni Choueiri outlines the results of the phase 3 KEYNOTE-564 trial showing the benefit of adjuvant treatment with pembrolizumab in patients with high-risk renal cell carcinoma (3:03).
View more on Medicine Matters oncology: [ Ссылка ]